Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice

Diabetologia

Volumn 54, Issue 5, 2011, Pages 1181-1189

  Song, D ^a   Bandsma, R H J ^a   Xiao, C ^a   Xi, L ^a   Shao, W ^a   Jin, T ^a   Lewis, G F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Cannabinoid receptor type 1; Glucose disappearance rate; Insulin resistance; Insulin sensitivity; Tissue glucose uptake

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; GLUCOSE; PROTEIN KINASE B;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; WILD TYPE;

ANIMALS; CENTRAL NERVOUS SYSTEM; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; PHOSPHORYLATION; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 79954629673     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2082-z     Document Type: Article

References (50)

1. J Aranceta B Moreno M Moya A Anadon 2009 Prevention of overweight and obesity from a public health perspective Nutr Rev 67 S83 S88 19453686 10.1111/j.1753-4887.2009.00166.x
2. JP Despres A Golay L Sjostrom 2005 Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia N Engl J Med 353 2121 2134 16291982 10.1056/NEJMoa044537 1:CAS:528:DC%2BD2MXht1ajtL3F (Pubitemid 41653104)
3. V Di Marzo JP Despres 2009 CB1 antagonists for obesity-what lessons have we learned from rimonabant? Nat Rev Endocrinol 5 633 638 19844251 10.1038/nrendo.2009.197
4. FX Pi-Sunyer LJ Aronne HM Heshmati J Devin J Rosenstock 2006 Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial JAMA 295 761 775 16478899 10.1001/jama.295.7.761 1:CAS:528:DC%2BD28XhsFOrs7g%3D (Pubitemid 43244304)
5. I Matias MV Di 2007 Endocannabinoids and the control of energy balance Trends Endocrinol Metab 18 27 37 17141520 10.1016/j.tem.2006.11.006 1:CAS:528:DC%2BD2sXhsFelsg%3D%3D (Pubitemid 44960014)
6. U Pagotto G Marsicano D Cota B Lutz R Pasquali 2006 The emerging role of the endocannabinoid system in endocrine regulation and energy balance Endocr Rev 27 73 100 16306385 10.1210/er.2005-0009 1:CAS:528:DC%2BD28XitFSitL4%3D (Pubitemid 43228239)
7. M Bensaid M Gary-Bobo A Esclangon, et al. 2003 The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells Mol Pharmacol 63 908 914 12644592 10.1124/mol.63.4.908 1:CAS:528:DC%2BD3sXisFeksb0%3D (Pubitemid 36368998)
8. P Cavuoto AJ McAinch G Hatzinikolas D Cameron-Smith GA Wittert 2007 Effects of cannabinoid receptors on skeletal muscle oxidative pathways Mol Cell Endocrinol 267 63 69 17270342 10.1016/j.mce.2006.12.038 1:CAS:528: DC%2BD2sXisVWmtLo%3D
9. P Cavuoto AJ McAinch G Hatzinikolas A Janovska P Game GA Wittert 2007 The expression of receptors for endocannabinoids in human and rodent skeletal muscle Biochem Biophys Res Commun 364 105 110 17935697 10.1016/j.bbrc.2007.09. 099 1:CAS:528:DC%2BD2sXht1aktb3F (Pubitemid 47599452)
10. D Cota G Marsicano M Tschop, et al. 2003 The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis J Clin Invest 112 423 431 12897210 1:CAS:528:DC%2BD3sXmtFemtrg%3D (Pubitemid 38063771)
11. D Osei-Hyiaman M DePetrillo P Pacher, et al. 2005 Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity J Clin Invest 115 1298 1305 15864349 1:CAS:528:DC%2BD2MXktFSktLw%3D (Pubitemid 40629049)
12. AW Herling M Gossel G Haschke, et al. 2007 CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats Am J Physiol Endocrinol Metab 293 E826 E832 17595216 10.1152/ajpendo.00264.2007 1:CAS:528:DC%2BD2sXhtVOqsb3E (Pubitemid 47358996)
13. TC Ravinet M Arnone C Delgorge, et al. 2003 Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice Am J Physiol Regul Integr Comp Physiol 284 R345 R353 (Pubitemid 36120150)
14. AW Herling S Kilp R Elvert G Haschke W Kramer 2008 Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed Wistar rats Endocrinology 149 2557 2566 18276749 10.1210/en.2007-1515 1:CAS:528:DC%2BD1cXht1Gmsb7O (Pubitemid 351574492)
15. D Cota DA Sandoval M Olivieri, et al. 2009 Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism Obesity (Silver Spring) 17 1641 1645 10.1038/oby.2009.84 1:CAS:528:DC%2BD1MXptlKnuro%3D
16. TC Ravinet C Delgorge C Menet M Arnone P Soubrie 2004 CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity Int J Obes 28 640 648 10.1038/sj.ijo.0802583 (Pubitemid 38491158)
17. AW Herling S Kilp HP Juretschke C Neumann-Haefelin M Gerl W Kramer 2008 Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant Int J Obes (Lond) 32 1363 1372 10.1038/ijo.2008.105 1:CAS:528:DC%2BD1cXhtFWhtbfK
18. J Tam VK Vemuri J Liu, et al. 2010 Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity J Clin Invest 120 2953 2966 20664173 10.1172/JCI42551 1:CAS:528:DC%2BC3cXhtVaiurzM
19. G Kunos 2007 Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med 120 S18 S24 17720356 10.1016/j.amjmed.2007.06.007 1:CAS:528:DC%2BD2sXhtlGgs7nL (Pubitemid 47284984)
20. R Nogueiras C Veyrat-Durebex PM Suchanek, et al. 2008 Peripheral, but not central, CB1 antagonism provides food intake independent metabolic benefits in diet-induced obese rats Diabetes 57 2977 2991 18716045 10.2337/db08-0161 1:CAS:528:DC%2BD1MXhsleisr0%3D
21. D Osei-Hyiaman J Liu L Zhou, et al. 2008 Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice J Clin Invest 118 3160 3169 18677409 10.1172/JCI34827 1:CAS:528:DC%2BD1cXhtV2isbvP
22. A Zimmer AM Zimmer AG Hohmann M Herkenham TI Bonner 1999 Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice Proc Natl Acad Sci USA 96 5780 5785 10318961 10.1073/pnas.96.10.5780 1:CAS:528:DyaK1MXjtFCnuro%3D (Pubitemid 29234695)
23. VS Dalton H Wang K Zavitsanou 2009 HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat Neurochem Res 34 1343 1353 19169813 10.1007/s11064-009-9914-y 1:CAS:528:DC%2BD1MXpvFajtA%3D%3D
24. D Giuliani A Ottani F Ferrari 2000 Effects of the cannabinoid receptor agonist, HU 210, on ingestive behaviour and body weight of rats Eur J Pharmacol 391 275 279 10729369 10.1016/S0014-2999(00)00069-8 1:CAS:528: DC%2BD3cXhvVOqurk%3D (Pubitemid 30154095)
25. L Robinson AV Goonawardena RG Pertwee RE Hampson G Riedel 2007 The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats Br J Pharmacol 151 688 700 17502849 10.1038/sj.bjp.0707273 1:CAS:528:DC%2BD2sXntFemtro%3D (Pubitemid 47016297)
26. RZ Chen A Frassetto TM Fong 2006 Effects of the CB1 cannabinoid receptor inverse agonist AM251 on food intake and body weight in mice lacking μ-opioid receptors Brain Res 1108 176 178 16828068 10.1016/j.brainres.2006.06.006 1:CAS:528:DC%2BD28XovVShurk%3D (Pubitemid 44278002)
27. N Irwin K Hunter N Frizzell PR Flatt 2008 Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB(1)) antagonist, AM251, in obese diabetic (ob/ob) mice Eur J Pharmacol 581 226 233 18191122 10.1016/j.ejphar.2007.12.003 1:CAS:528:DC%2BD1cXhsVCmsL0%3D
28. N Irwin K Hunter PR Flatt 2008 Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice Peptides 29 1036 1041 18291559 10.1016/j.peptides.2008.01.006 1:CAS:528:DC%2BD1cXlvVCls7g%3D
29. AM Mistry AG Swick DR Romsos 1997 Leptin rapidly lowers food intake and elevates metabolic rates in lean and ob/ob mice J Nutr 127 2065 2072 9311966 1:CAS:528:DyaK2sXmsV2lsbg%3D (Pubitemid 27424448)
30. JK Kim O Gavrilova Y Chen ML Reitman GI Shulman 2000 Mechanism of insulin resistance in A-ZIP/F-1 fatless mice J Biol Chem 275 8456 8460 10722680 10.1074/jbc.275.12.8456 1:CAS:528:DC%2BD3cXit1enur8%3D (Pubitemid 30180190)
31. Franklin F, Paxinos G (1998) The mouse brain in stereotaxic coordinates. Academic Press, Sydney
32. JL Osborn AK Camara 1997 Renal neurogenic mediation of intracerebroventricular angiotensin II hypertension in rats raised on high sodium chloride diet Hypertension 30 331 336 9314413 1:CAS:528: DyaK2sXmsV2hs70%3D (Pubitemid 27446089)
33. K Ohshima NS Shargill TM Chan GA Bray 1984 Adrenalectomy reverses insulin resistance in muscle from obese (ob/ob) mice Am J Physiol 246 E193 E197 6421176 1:CAS:528:DyaL2cXhtlKqtb4%3D (Pubitemid 14147695)
34. JE Ayala DP Bracy OP McGuinness DH Wasserman 2006 Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse Diabetes 55 390 397 16443772 10.2337/diabetes.55.02.06.db05-0686 1:CAS:528: DC%2BD28XhsFajs70%3D (Pubitemid 43343268)
35. CH Wang N Leung N Lapointe, et al. 2003 Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker Circulation 107 1923 1929 12668518 10.1161/01.CIR.0000062646. 09566.CC 1:CAS:528:DC%2BD3sXis12qu7k%3D (Pubitemid 36444136)
36. DC Bradley GM Steil RN Bergman 1993 Quantitation of measurement error with optimal segments: basis for adaptive time course smoothing Am J Physiol 264 E902 E911 8333516 1:STN:280:DyaK3szisFKqsg%3D%3D (Pubitemid 23198565)
37. JH Youn JK Kim TA Buchanan 1994 Time courses of changes in hepatic and skeletal muscle insulin action and GLUT4 protein in skeletal muscle after STZ injection Diabetes 43 564 571 8138062 10.2337/diabetes.43.4.564 1:CAS:528:DyaK2cXktVKntbg%3D (Pubitemid 24096298)
38. J Shao H Yamashita L Qiao JE Friedman 2000 Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Leprdb/db mice J Endocrinol 167 107 115 11018758 10.1677/joe.0.1670107 1:CAS:528:DC%2BD3MXptVeitA%3D%3D
39. W Shao Z Yu IG Fantus T Jin 2010 Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic beta-cells Cell Signal 22 1240 1246 20385228 10.1016/j.cellsig.2010.04.001 1:CAS:528:DC%2BC3cXmtlyntbc%3D
40. T Jourdan L Djaouti L Demizieux J Gresti B Verges P Degrace 2010 CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice Diabetes 59 926 934 20110567 10.2337/db09-1482 1:CAS:528:DC%2BC3cXltFSmt7w%3D
41. K Eckardt H Sell A Taube, et al. 2009 Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle Diabetologia 52 664 674 19089403 10.1007/s00125-008-1240-4 1:CAS:528:DC%2BD1MXisFSjurc%3D
42. CK Lam M Chari TK Lam 2009 CNS regulation of glucose homeostasis Physiology (Bethesda) 24 159 170 1:CAS:528:DC%2BD1MXosVyitrg%3D
43. I Greenberg J Kuehnle JH Mendelson JG Bernstein 1976 Effects of marihuana use on body weight and caloric intake in humans Psychopharmacology (Berl) 49 79 84 1:STN:280:DyaE283ntVWmsQ%3D%3D
44. J LoVerme A Duranti A Tontini, et al. 2009 Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice Bioorg Med Chem Lett 19 639 643 19128970 10.1016/j.bmcl.2008.12.059 1:CAS:528:DC%2BD1MXhtF2ju7k%3D
45. C Lipina C Stretton S Hastings, et al. 2010 Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells Diabetes 59 375 385 19933999 10.2337/db09-0979 1:CAS:528:DC%2BC3cXhvVyrurk%3D
46. I Esposito MC Proto P Gazzerro, et al. 2008 The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase Mol Pharmacol 74 1678 1686 18801918 10.1124/mol.108.049205 1:CAS:528:DC%2BD1cXhsVGls7rI
47. B Poirier JP Bidouard C Cadrouvele, et al. 2005 The anti-obesity effect of rimonabant is associated with an improved serum lipid profile Diabetes Obes Metab 7 65 72 15642077 10.1111/j.1463-1326.2004.00374.x 1:CAS:528: DC%2BD2MXhsFGhtLY%3D
48. AE Civitarese B Ukropcova S Carling, et al. 2006 Role of adiponectin in human skeletal muscle bioenergetics Cell Metab 4 75 87 16814734 10.1016/j.cmet.2006.05.002 1:CAS:528:DC%2BD28XmvFyhsr8%3D (Pubitemid 43942255)
49. S Engeli K Heusser J Janke, et al. 2008 Peripheral endocannabinoid system activity in patients treated with sibutramine Obesity Silver Spring 16 1135 1137 18356837 10.1038/oby.2008.47 1:CAS:528:DC%2BD1cXltlGjt7c%3D (Pubitemid 351620487)
50. S Migrenne A Lacombe AL Lefevre, et al. 2009 Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice Am J Physiol Regul Integr Comp Physiol 296 R929 R935 19211723 10.1152/ajpregu.90824.2008 1:CAS:528:DC%2BD1MXkvVygtb8%3D